MedTrace Logo

A Study of LY2940680 in Japanese Participants With Advanced Cancers

NCT01919398 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-09-11

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.

Conditions

  • Neoplasm Metastasis

Interventions

DRUG

LY2940680

Administered orally

Sponsors & Collaborators

Principal Investigators

  • 1-858-255-5959 Mon-Fri from 9 AM to 5 PM Pacific Time (PST) · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-05-31
Completion
2017-06-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01919398 on ClinicalTrials.gov